Log In
BCIQ
Print this Print this
 

FoundationOne Heme

  Manage Alerts
Collapse Summary General Information
Company Foundation Medicine Inc.
DescriptionLaboratory-developed test (LDT) that identifies all somatically altered genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples that are validated targets for therapy or drivers of oncogenesis
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics: Biomarkers and companion diagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsProfile genomic alterations in hematologic malignancies, sarcomas and pediatric cancers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,000.0M

$780.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/14/2015

$1,000.0M

$780.0M

0

01/12/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today